Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 43,600 |
|
|||||
| News | (2) |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Conduit Pharmaceuticals Inc | CDTTW | NASDAQ | Equity Warrant |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.00265 | -19.11% | 0.0112 | 15:00:48 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0151 | 0.0111 | 0.0177 | 0.0112 | 0.013846 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
|---|---|---|---|---|
| 40 | 43,600 | 0.0149868 | 653 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 29 | 0.0138 | USD |
Conduit Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.01M | 72.81M | - | 0 | -6.06M | -0.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Conduit Pharmaceuticals
| Date | Time | Source | Heading |
|---|---|---|---|
| 2/19/2025 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/19/2025 | 08:00 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2/14/2025 | 16:11 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2/12/2025 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 2/11/2025 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/10/2025 | 15:30 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2/06/2025 | 16:19 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 2/06/2025 | 07:58 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2/05/2025 | 16:30 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 1/23/2025 | 07:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/21/2025 | 16:00 | Edgar (US Regulatory) | Form SCHEDULE 13G - Statement of Beneficial Ownership by.. |
| 1/15/2025 | 15:30 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
CDTTW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto's Thyroiditis. The Company's asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto's Thyroiditis (HT) and Graves' disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto's Thyroiditis and Graves' disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). |
NASDAQ:CDTTW -
What is the current Conduit Pharmaceuticals Inc share price?
The current share price of Conduit Pharmaceuticals Inc is US$ 0.0112
How many Conduit Pharmaceuticals Inc shares are in issue?
Conduit Pharmaceuticals Inc has 72,814,000 shares in issue
What is the market cap of Conduit Pharmaceuticals Inc?
The market capitalisation of Conduit Pharmaceuticals Inc is USD 1.01M
What is the 1 year trading range for Conduit Pharmaceuticals Inc share price?
Conduit Pharmaceuticals Inc has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Conduit Pharmaceuticals Inc?
The price to earnings ratio of Conduit Pharmaceuticals Inc is -202.52
What is the reporting currency for Conduit Pharmaceuticals Inc?
Conduit Pharmaceuticals Inc reports financial results in USD
What is the latest annual profit for Conduit Pharmaceuticals Inc?
The latest annual profit of Conduit Pharmaceuticals Inc is USD -6.06M
What is the registered address of Conduit Pharmaceuticals Inc?
The registered address for Conduit Pharmaceuticals Inc is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Conduit Pharmaceuticals Inc website address?
The website address for Conduit Pharmaceuticals Inc is www.conduitpharma.com
Which industry sector does Conduit Pharmaceuticals Inc operate in?
Conduit Pharmaceuticals Inc operates in the PHARMACEUTICAL PREPARATIONS sector
